Clinical Utility of PET/CT in Lymphoma

被引:92
作者
Cronin, Carmel G. [1 ]
Swords, Ronan [3 ]
Truong, Mylene T. [4 ]
Viswanathan, Chitra [4 ]
Rohren, Eric [4 ]
Giles, Francis J. [3 ]
O'Dwyer, Michael [2 ]
Bruzzi, John F. [1 ]
机构
[1] Galway Univ Hosp, Univ Coll Hosp Galway, Dept Radiol, Galway, Ireland
[2] Galway Univ Hosp, Univ Coll Hosp Galway, Dept Hematol, Galway, Ireland
[3] Univ Texas Hlth Sci Ctr San Antonio, Div Hematol & Med Oncol, Canc Therapy & Res Ctr, Inst Drug Dev, San Antonio, TX 78229 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Imaging, Houston, TX 77030 USA
关键词
lymphoma; PET/CT; POSITRON-EMISSION-TOMOGRAPHY; NON-HODGKINS-LYMPHOMA; F-18; FDG-PET; MALIGNANT-LYMPHOMA; PROGNOSTIC VALUE; POSTTREATMENT EVALUATION; AGGRESSIVE LYMPHOMA; RESPONSE ASSESSMENT; TREATMENT FAILURE; PROGRESSION-FREE;
D O I
10.2214/AJR.09.2637
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. The purpose of this review is to assist interpreting radiologists in becoming familiar with the role of PET/CT in baseline staging and therapeutic response assessment in the management of lymphoma, in becoming aware of imaging pitfalls, and in understanding the natural behavior of lymphoma and the therapeutic options. CONCLUSION. Therapeutic strategies for the management of lymphoma are constantly being refined to improve long-term survival with the lowest risk of toxicity to the patient. PET/CT is accurate for baseline staging and yields important prognostic information for determining the most appropriate initial treatment. Used for evaluation of treatment response, PET/CT can depict residual viable malignant lesions with greater accuracy than can other imaging techniques. The findings thereby influence decisions about the need for additional or alternative treatment.
引用
收藏
页码:W91 / W103
页数:13
相关论文
共 61 条
[31]   Abdominal manifestations of extranodal lymphoma: Spectrum of imaging findings [J].
Lee, Wai-Kit ;
Lau, Eddie W. F. ;
Duddalwar, Vinay A. ;
Stanley, Anthony J. ;
Ho, Yvonne Y. .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2008, 191 (01) :198-206
[32]   FDG PET of infection and inflammation [J].
Love, C ;
Tomas, MB ;
Tronco, GG ;
Palestro, CJ .
RADIOGRAPHICS, 2005, 25 (05) :1357-1368
[33]   Extranodal nonorbital indolent lymphomas of the head and neck: Relationship between tumor control and radiotherapy [J].
MacDermed, D ;
Thurber, L ;
George, TI ;
Hoppe, RT ;
Le, QT .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (03) :788-795
[34]   Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma [J].
Martin, WG ;
Ristow, KM ;
Habermann, TM ;
Colgan, JP ;
Witzig, TE ;
Ansell, SM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7614-7620
[35]   Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT:: Characterization and incidence [J].
Metser, Ur ;
Miller, Elka ;
Lerman, Hedva ;
Even-Sapir, Einat .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2007, 189 (05) :1203-1210
[36]   FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma [J].
Mikhaeel, NG ;
Hutchings, M ;
Fields, PA ;
O'Doherty, MJ ;
Timothy, AR .
ANNALS OF ONCOLOGY, 2005, 16 (09) :1514-1523
[37]   18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas [J].
Mikhaeel, NG ;
Timothy, AR ;
Hain, SF ;
O'Doherty, MJ .
ANNALS OF ONCOLOGY, 2000, 11 :147-150
[38]   18-F-fluorodeoxyglucose positron emission tomography as a new approach to detect lymphomatous bone marrow [J].
Moog, F ;
Bangerter, M ;
Kotzerke, J ;
Guhlmann, A ;
Frickhofen, N ;
Reske, SN .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :603-609
[39]   Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma [J].
Naumann, R ;
Beuthien-Baumann, B ;
Reiss, A ;
Schulze, J ;
Hänel, A ;
Bredow, J ;
Kühnel, G ;
Kropp, J ;
Hänel, M ;
Laniaso, M ;
Kotzerke, J ;
Ehninger, G .
BRITISH JOURNAL OF CANCER, 2004, 90 (03) :620-625
[40]   Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma [J].
Naumann, R ;
Vaic, A ;
Beuthien-Baumann, B ;
Bredow, J ;
Kropp, J ;
Kittner, T ;
Franke, WG ;
Ehninger, G .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (04) :793-800